---
title: "Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286575139.md"
description: "Dogwood Therapeutics reported Q1 2026 revenue of $2.41M, with a net loss of $4.99M and diluted EPS of ($0.15), showing significant improvement year-over-year. The company is advancing its clinical programs, including the ongoing Phase 2b trial of Halneuron® and a new program for CIPN. Recent equity financing has extended operational funding into Q4 2026. Halneuron® has received FDA fast-track designation, although risks remain regarding clinical and market setbacks."
datetime: "2026-05-15T13:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286575139.md)
  - [en](https://longbridge.com/en/news/286575139.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286575139.md)
generator: "portal-rs"
---

# Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary

Dogwood Therapeutics reported first-quarter 2026 results with revenue of $2.41M and a net loss attributable to common stockholders of ($4.99M), or diluted EPS of ($0.15), improving versus the prior-year quarter as the company advances clinical programs and completed equity financings in January 2026.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$2.41M

$1.99M

20.8%

Net income²

($4.99M)

($12.18M)

59.1%

Diluted EPS³

($0.15)

($8.45)

98.2%

*¹ Reported as “Revenue”. ² Reported as “Net loss attributable to common stockholders”. ³ Reported as “loss per common share, basic and diluted”.*

**Business Highlights**

-   Pipeline progress: Halneuron® Phase 2b ongoing with 164 patients enrolled; top-line data expected in fall 2026 and interim results showed a treatment effect.
-   New program: SP16 IV licensed for chemotherapy-induced peripheral neuropathy (CIPN); IND accepted by the FDA and NCI-funded Phase 1b dosing expected to start mid-2026.
-   Portfolio optimization: Rights to IMC-1 and IMC-2 assigned to PRIDCor while Dogwood retains tiered royalties and potential participation in future financing.
-   Operational funding: January 2026 equity offerings provided approximately $11.4M in net cash, extending runway into Q4 2026 to support ongoing trials.
-   Regulatory: Halneuron® granted FDA fast-track designation for CINP; company notes IPR&D and goodwill could be at risk if clinical or market setbacks occur.

Original SEC Filing: Dogwood Therapeutics, Inc. \[ DWTX \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DWTX.US](https://longbridge.com/en/quote/DWTX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS](https://longbridge.com/en/news/295832761.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**